Form 4: Seres Therapeutics Executive Lisa von Moltke Reports Stock Transactions
SEC Form 4 Filing
Lisa von Moltke, Executive Vice President and Chief Medical Officer of Seres Therapeutics, reports the vesting and sale of restricted stock units to cover taxes.
Summary
- Lisa von Moltke, an executive at Seres Therapeutics, reported transactions involving the company's common stock.
- On October 27, 2024, 13,744 restricted stock units (RSUs) vested and were settled, converting into shares of common stock.
- These RSUs were part of an award granted on February 3, 2023, which vested in two installments based on performance criteria.
- The first installment vested on October 27, 2023, and the second on October 27, 2024.
- On October 28, 2024, Ms. von Moltke sold 4,334 shares of common stock at an average price of $0.6902 per share.
- The sales were executed under a Rule 10b5-1 trading plan adopted on July 2, 2023, to cover taxes related to the vesting of the RSUs.
- Following these transactions, Ms. von Moltke beneficially owns 30,423 shares of Seres Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, which carries a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the biopharmaceutical industry.
Stakeholder Impact
- The stock sale by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the context of tax obligations.
Key Dates
| Date | Description |
|---|---|
| 2023-02-03 | Reporting person was granted an award of 27,489 restricted stock units (RSUs). |
| 2023-04-27 | Initial Milestone Date: The Issuer's Administrator determined that the performance criteria for the first installment were met. |
| 2023-07-02 | Rule 10b5-1 instruction adopted by the reporting person. |
| 2023-10-27 | First installment of RSUs (13,745) vested and settled. |
| 2024-10-27 | Second installment of RSUs (13,744) vested and settled. |
| 2024-10-28 | 4,334 shares of common stock were sold at an average price of $0.6902. |
| 2024-10-29 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.